Blog

3 Takeaways from the World Vaccine Congress 2018

BIO 2018: The Emergence of Gene & Cell Therapy

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Controlling Impurities in Cell Culture Media

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

Happy Holidays from the InVitria Team!

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Improvement of Vaccine Manufacturing Process with Use of Recombinant HSA Excipient

InVitria at the American Association of Immunologists 2018 Conference

InVitria Expands European and UK Footprint

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

InVitria’s Top Insights from ISCT 2018 – Montreal

Join InVitria at Phacilitate 2019

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Solving the Vaccine Supply Challenge

The Emergence of Serum-Free Cell Culture Media – Blood-Free Chemically Defined Components

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial